Project UpdateMay 26, 2026, 08:32 AM
Cocrystal Pharma Discovers Pan-Viral Inhibitors for Hantavirus, Influenza
AI Summary
Cocrystal Pharma announced the discovery of novel direct-acting antivirals demonstrating pan-viral activity against hantavirus, bunyavirus, and influenza. These inhibitors target a highly conserved region of the viral replication enzyme, showing superior in vitro potency against hantaan virus. This development addresses significant unmet medical needs, as there are currently no approved treatments or vaccines for hantavirus and bunyavirus infections. The company plans to further evaluate these inhibitors and explore potential collaborations.
Key Highlights
- Cocrystal Pharma discovered novel direct-acting antivirals with pan-viral activity.
- Inhibitors target hantavirus, bunyavirus, and influenza by targeting the viral replication enzyme.
- In vitro potency data show superior activity (IC50 <50 nM) against hantaan virus.
- Hantavirus and bunyavirus infections represent significant unmet medical needs with no approved treatments or vaccines.
- The company is leveraging its structure-based drug discovery platform for next-generation antiviral candidates.
- Another pan-viral protease inhibitor, CDI-988, recently advanced to a Phase 1b norovirus challenge study.
Price Impact
More from COCP